Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lurasidone Beats Placebo In Phase III, But Zyprexa Arm Could Confound

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Dainippon Sumitomo Pharma Co. has enough positive pivotal trials for its planned 2010 NDA filing for the atypical antipsychotic lurasidone, but newly released data from one of those trials reveal a discrepancy in the efficacy results that could be a hurdle at FDA.

You may also be interested in...



Atypical Antipsychotic Market Snapshot: Making Way For Three New Drugs

Three newly-approved drugs - Schering Plough's Saphris, Johnson & Johnson's Invega Sustenna and Vanda's Fanapt - are poised to enter the atypical antipsychotic space despite the crowd of approved products and the specter of market genericization

Schering Likely To Play Up Saphris' Safety In Q4 Launch

Clearance for schizophrenia and bipolar disorder in one fell swoop marks a first in the crowded class of atypical anti-psychotics.

Panel Recommends Schering's Saphris; Safety Profile Could Provide Niche

The atypical antipsychotic market should soon be seeing competition from a new entry with a novel formulation and a more attractive safety profile, after an FDA advisory committee voted strongly in favor of Schering Plough's Saphris (asenapine) for acute schizophrenia and bipolar disorder

Related Content

Topics

UsernamePublicRestriction

Register

LL111799

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel